Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial, page-71

https://www.renaissancecapital.com/IPO-Center/News/103151/Brain-cancer-biotech-NeOnc-Technologies-sets-terms-for-$75-million-IPO

Brain cancer biotech NeOnc Technologies sets terms for $75 million IPO

This should give us a little idea of how undervalued we are.

The Westlake Village, CA-based company plans to raise $75 million by offering 3.8 million shares at a price range of $18.75 to $20.75. At the midpoint of the proposed range, NeOnc Technologies Holdings would command a fully diluted market value of $466 million.

NeOnc has 2 therapy candidates:

- NEO100, is a purified form of perillyl acid which is administered to brain cancer patients via intranasal delivery. The company is currently conducting a Phase 2a trial of NEO100 in recurrent malignant glioma patients, as well as a similar Phase 2a trial in patients with malignant skull-based meningioma. It expects a readout for its Phase 2 studies of NEO100 by the end of 2024.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879254/

- NEO212, is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 has completed preclinical testing, and in the 4Q23, it entered a Phase 1/2 trial as an oral therapy in patients with primary and secondary brain tumors.